Approval Expands Takeda’s Portfolio of Differentiated Immunoglobulin Therapies and Reflects the Company’s Commitment to Bring High-Quality Plasma-Derived Therapies to Patients in Japan ...
The European Commission approved Tagrisso for the treatment of adults with locally advanced, unresectable NSCLC whose tumors have EGFR exon 19 deletions or exon 21 substitution (L858R) mutations and ...